NEW YORK – Global law firm Reed Smith today announced that it recently advised Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) in a reverse merger with Qualigen, Inc., a privately held company, in an all-stock transaction.
Graph with beaker blurred

Ritter Pharmaceuticals is a developer of therapeutic products that modulate the gut microbiome to treat gastrointestinal diseases. Qualigen focuses on the development and commercialization of novel therapeutic products for the treatment of cancer and infectious diseases.

The cross-practice Reed Smith team on this transaction was led by corporate partner Jennifer W. Cheng with key support from partners Wendy Grasso and Michael Sanders, counsel Sue Nieto, and associates Sheran Sharafi, Nataly Laufer Sultan, Iantha Stewart, Brent McDonough and Emerson Bianchi.

A copy of the press release issued by Ritter announcing the acquisition can be found at